MAPK1 and non-small cell lung carcinoma: Therefore, YAP has been suggested to be involved in the promotion of resistance to therapies targeting the EGFR/Ras/Raf/MEK/ERK pathway, and it represents a therapeutic target for metastatic NSCLC.